{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:01:31Z","timestamp":1790053291098,"version":"4.0.1"},"reference-count":40,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Dr. Mariam and Sheldon Adelson Medical Research Foundation"},{"name":"Nakayama Foundation for Human Science","id":[{"id":"https:\/\/ror.org\/00d57n961","id-type":"ROR","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/00d57n961","id-type":"ROR","asserted-by":"publisher"}]},{"name":"Cori Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Background: Intrahepatic cholangiocarcinoma (iCCA) is an aggressive biliary tract malignancy with limited treatment options and poor prognosis. Platinum-based drugs are one of the major therapies; however, resistance remains a major therapeutic challenge. Ubiquilin-4 (UBQLN4), a ubiquitin-binding protein implicated in cancer progression and DNA damage responses, is located at chromosome 1q22, a region recurrently amplified in several cancers. We investigated the clinical and functional relevance of UBQLN4 in iCCA. Methods: Public datasets (TCGA-CHOL and GSE107943) were analyzed to identify genomic alterations and UBQLN4 expression in iCCA. UBQLN4 mRNA expression was evaluated in an independent clinical cohort and correlated with patient outcomes. Functional studies using iCCA cell lines and three-dimensional spheroid models examined the role of UBQLN4 in cisplatin resistance. Results: Chromosome 1q22, containing UBQLN4, was among the recurrently amplified regions in TCGA-CHOL. UBQLN4 mRNA expression correlated with copy number amplification and was significantly higher in iCCA than in normal liver tissue in both datasets. In the validation cohort, higher UBQLN4 mRNA expression was associated with shorter recurrence-free survival (p = 0.025) and remained associated with shorter recurrence-free survival after adjustment for clinicopathological factors (HR = 2.44; 95% CI 1.14\u20135.20; p = 0.022). Higher UBQLN4 expression was also associated with poorer pathological response to cisplatin-containing neoadjuvant chemotherapy. In iCCA cell lines, UBQLN4 knockdown increased cisplatin sensitivity, whereas cisplatin-resistant derivatives showed increased UBQLN4 expression. Conclusions: Elevated UBQLN4 expression is associated with adverse clinical outcomes and reduced response to cisplatin-containing chemotherapy in iCCA, while functional studies support a potential role for UBQLN4 in modulating cisplatin sensitivity. These findings identify UBQLN4 as a potential biomarker and therapeutic candidate that warrants further independent and prospective validation.<\/jats:p>","DOI":"10.3390\/cells15181697","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T09:01:38Z","timestamp":1789981298000},"page":"1697","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["UBQLN4 Is a Prognostic Biomarker in Intrahepatic Cholangiocarcinoma That Is Associated with Cisplatin Resistance"],"prefix":"10.3390","volume":"15","author":[{"given":"Kodai","family":"Abe","sequence":"first","affiliation":[{"name":"Department of Translational Molecular Medicine, Saint John\u2019s Cancer Institute (SJCI), Saint John\u2019s Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA"},{"name":"Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"writing-original-draft","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6219-4088","authenticated-orcid":false,"given":"Kelly","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Medicine, Saint John\u2019s Cancer Institute (SJCI), Saint John\u2019s Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"software","vocabulary":"credit"},{"role":"formal-analysis","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5840-8901","authenticated-orcid":false,"given":"Yuta","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4909-1199","authenticated-orcid":false,"given":"Minoru","family":"Kitago","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"resources","vocabulary":"credit"}]},{"given":"Motonori","family":"Edanami","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"}]},{"given":"Yosuke","family":"Uematsu","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"validation","vocabulary":"credit"}]},{"given":"Yohei","family":"Masugi","sequence":"additional","affiliation":[{"name":"Department of Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"},{"name":"Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9428-4128","authenticated-orcid":false,"given":"Akihisa","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University School of Medicine, Isehara 259-1193, Kanagawa, Japan"},{"name":"Division of Diagnostic Pathology, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9625-1127","authenticated-orcid":false,"given":"Matias A.","family":"Bustos","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Medicine, Saint John\u2019s Cancer Institute (SJCI), Saint John\u2019s Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA"},{"name":"Department of Translational and Precision Medicine, Saint John\u2019s Cancer Institute (SJCI), Saint John\u2019s Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"writing-review-editing","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7251-2828","authenticated-orcid":false,"given":"Anton J.","family":"Bilchik","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal and Hepatobiliary Surgery, Saint John\u2019s Cancer Institute (SJCI), Saint John\u2019s Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"resources","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1538-6060","authenticated-orcid":false,"given":"Yosef","family":"Shiloh","sequence":"additional","affiliation":[{"name":"David and Inez Myers Laboratory for Cancer Genetics, Department of Human Genetics and Computational Medicine, Gray Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"funding-acquisition","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Yuko","family":"Kitagawa","sequence":"additional","affiliation":[{"name":"Department of Surgery, Keio University School of Medicine, Shinjuku 160-8582, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"}]},{"given":"Dave S. B.","family":"Hoon","sequence":"additional","affiliation":[{"name":"Department of Translational Molecular Medicine, Saint John\u2019s Cancer Institute (SJCI), Saint John\u2019s Health Center (SJHC), Providence Health System (PHS), Santa Monica, CA 90404, USA"},{"name":"Advanced Therapeutics and Biomedical Technologies, The Lundquist Institute of Biomedical Innovation, Harbor-UCLA Medical Center, Torrance, CA 90504, USA"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"},{"role":"project-administration","vocabulary":"credit"},{"role":"funding-acquisition","vocabulary":"credit"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref_1","first-page":"198","article-title":"Advances in the treatment of intrahepatic cholangiocarcinoma: An overview of the current and future therapeutic landscape for clinicians","volume":"73","author":"Moris","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e2500402","DOI":"10.1200\/PO-25-00402","article-title":"Intrahepatic Cholangiocarcinoma: Recurrence Patterns, Genomics, and Survival","volume":"9","author":"Chandra","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"Valle","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jhep.2019.03.013","article-title":"Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma","volume":"71","author":"Bertuccio","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","article-title":"Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial","volume":"7","author":"Zhu","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"EASL-ILCA (2023). Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J. Hepatol., 79, 181\u2013208.","DOI":"10.1016\/j.jhep.2023.03.010"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","article-title":"Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Vogel","year":"2023","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e478s","DOI":"10.6061\/clinics\/2018\/e478s","article-title":"DNA repair pathways and cisplatin resistance: An intimate relationship","volume":"73","author":"Rocha","year":"2018","journal-title":"Clinics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nrd1691","article-title":"Cellular processing of platinum anticancer drugs","volume":"4","author":"Wang","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/nrc3399","article-title":"DNA repair dysregulation from cancer driver to therapeutic target","volume":"12","author":"Curtin","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/1878-0261.12929","article-title":"Regulation of MRE11A by UBQLN4 leads to cisplatin resistance in patients with esophageal squamous cell carcinoma","volume":"15","author":"Murakami","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e985","DOI":"10.1002\/ctm2.985","article-title":"UBQLN4 promotes STING proteasomal degradation during cisplatin-induced DNA damage in triple-negative breast cancer","volume":"12","author":"Shoji","year":"2022","journal-title":"Clin. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"5748","DOI":"10.1074\/jbc.M709288200","article-title":"A Novel Connexin43-interacting Protein, CIP75, Which Belongs to the UbL-UBA Protein Family, Regulates the Turnover of Connexin43","volume":"283","author":"Li","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"40979","DOI":"10.1074\/jbc.M110.170753","article-title":"Ubiquitin-independent proteasomal degradation of endoplasmic reticulum-localized Connexin43 mediated by CIP75","volume":"285","author":"Su","year":"2010","journal-title":"J. Biol. Chem."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cell.2018.11.024","article-title":"UBQLN4 Represses Homologous Recombination and Is Overexpressed in Aggressive Tumors","volume":"176","author":"Jachimowicz","year":"2019","journal-title":"Cell"},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kobayashi, Y., Bustos, M.A., Shoji, Y., Jachimowicz, R.D., Shiloh, Y., and Hoon, D.S.B. (2022). Genomic Amplification of UBQLN4 Is a Prognostic and Treatment Resistance Factor. Cells, 11.","DOI":"10.3390\/cells11203311"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s12072-019-09954-3","article-title":"Prognostic subclass of intrahepatic cholangiocarcinoma by integrative molecular-clinical analysis and potential targeted approach","volume":"13","author":"Ahn","year":"2019","journal-title":"Hepatol. Int."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"R41","DOI":"10.1186\/gb-2011-12-4-r41","article-title":"GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers","volume":"12","author":"Mermel","year":"2011","journal-title":"Genome Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The Molecular Signatures Database (MSigDB) hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/archsurg.1992.01420110083017","article-title":"Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas","volume":"127","author":"Evans","year":"1992","journal-title":"Arch. Surg."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.hpb.2023.01.011","article-title":"Neoadjuvant chemotherapy for high-risk intrahepatic cholangiocarcinoma\u2014Does pathologic response mean better outcomes?","volume":"25","author":"Ayabe","year":"2023","journal-title":"HPB"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e70067","DOI":"10.1002\/ctm2.70067","article-title":"Induced collagen type-I secretion by hepatocytes of the melanoma liver metastasis is associated with a reduction in tumour-infiltrating lymphocytes","volume":"14","author":"Mizuno","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.ajpath.2022.05.007","article-title":"Development and Characterization of Human Primary Cholangiocarcinoma Cell Lines","volume":"192","author":"Isidan","year":"2022","journal-title":"Am. J. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e608","DOI":"10.1002\/ctm2.608","article-title":"Interleukin enhancer-binding factor 2 promotes cell proliferation and DNA damage response in metastatic melanoma","volume":"11","author":"Zhang","year":"2021","journal-title":"Clin. Transl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"101951","DOI":"10.1016\/j.mcp.2024.101951","article-title":"Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments","volume":"73","author":"Capuozzo","year":"2024","journal-title":"Mol. Cell Probes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"52","DOI":"10.21037\/cco.2018.07.03","article-title":"Intrahepatic cholangiocarcinoma: The AJCC\/UICC 8th edition updates","volume":"7","author":"Lee","year":"2018","journal-title":"Chin. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"3738","DOI":"10.1002\/1878-0261.13058","article-title":"UBQLN4 is an ATM substrate that stabilizes the anti-apoptotic proteins BCL2A1 and BCL2L10 in mesothelioma","volume":"15","author":"Liu","year":"2021","journal-title":"Mol. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamaoncol.2025.4736","article-title":"Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01","volume":"12","author":"Pant","year":"2026","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1158\/1078-0432.CCR-26-0428","article-title":"Molecular and Clinical Determinants of Targeted Therapy Treatment in Biliary Tract Cancer","volume":"32","author":"Cowzer","year":"2026","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"6304","DOI":"10.1245\/s10434-023-13818-4","article-title":"Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Potential Paradigm Shift in Treatment Sequencing","volume":"30","author":"Ejaz","year":"2023","journal-title":"Ann. Surg. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Liu, Y., Wu, C., Huang, Q., Zhou, Y., and Tang, K. (2025). Neoadjuvant chemotherapy followed by surgery versus upfront surgery for intrahepatic cholangiocarcinoma: A systematic review and meta-analysis. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-15203-8"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/j.jhep.2025.05.003","article-title":"Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study","volume":"83","author":"Oh","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12935-019-1078-5","article-title":"UBQLN4 promotes progression of HCC via activating wnt-\u03b2-catenin pathway and is regulated by miR-370","volume":"20","author":"Yu","year":"2020","journal-title":"Cancer Cell Int."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41420-021-00795-4","article-title":"UBQLN4 is activated by C\/EBP\u03b2 and exerts oncogenic effects on colorectal cancer via the Wnt\/\u03b2-catenin signaling pathway","volume":"7","author":"Tang","year":"2021","journal-title":"Cell Death Discov."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00432-024-05862-8","article-title":"UBQLN4 promotes the proliferation and invasion of non-small cell lung cancer cell by regulating PI3K\/AKT pathway","volume":"150","author":"He","year":"2024","journal-title":"J. Cancer Res. Clin. Oncol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/18\/1697\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T04:12:23Z","timestamp":1790050343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/15\/18\/1697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":40,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cells15181697"],"URL":"https:\/\/doi.org\/10.3390\/cells15181697","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}